• Cell Tracking in Cancer Immunotherapy, Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, et al, Front Med. 14 févr 2020;7:34. https://doi.org/10.3389/fmed.2020.00034

  • Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases, Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V, et al, Biomedicines. 28 nov 2020;8(12):548. https://doi.org/10.3390/biomedicines8120548

  • Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease, Gouard S, Maurel C, Marionneau-Lambot S, Dansette D, Bailly C, Guérard F, et al, Cancers. 22 sept 2020;12(9):2721. https://doi.org/10.3390/cancers12092721

  • Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project, Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, et al, Haematologica. janv 2020;105(1):e33‑6. https://doi.org/10.3324/haematol.2019.223016

  • Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer, Le Thiec M, Testard A, Ferrer L, Guillerminet C, Morel O, Maucherat B, et al, Cancers. 9 juin 2020;12(6):1512. https://doi.org/10.3390/cancers12061512

  • ImmunoPET in Multiple Myeloma—What? So What? Now What?, Bailly C, Chalopin B, Gouard S, Carlier T, Remaud-Le Saëc P, Marionneau-Lambot S, et al, Cancers. 4 juin 2020;12(6):1467. https://doi.org/10.3390/cancers12061467

  • Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma, Jamet B, Bailly C, Carlier T, Touzeau C, Michaud A-V, Bourgeois M, et al, Cancers. 19 févr 2020;12(2):486. https://doi.org/10.3390/cancers12020486

  • Haute Couture or Ready-To-Wear? Tailored Pelvic Radiotherapy for Prostate Cancer Based on Individualized Sentinel Lymph Node Detection, Michaud A-V, Samain B, Ferrer L, Fleury V, Dore M, Colombie M, et al, Cancers. 10 avr 2020;12(4):944. https://doi.org/10.3390/cancers12040944

  • Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials, Michaud-Robert A-V, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, et al, Cancers. 6 sept 2020;12(9):2532. https://doi.org/10.3390/cancers12092532

  • Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma, Jamet B, Zamagni E, Nanni C, Bailly C, Carlier T, Touzeau C, et al, IJMS. 29 juill 2020;21(15):5406. https://doi.org/10.3390/ijms21155406